MonoSol Rx Appoints James S. Scibetta to Board of Directors
WARREN, N.J., April 11, 2017 – MonoSol Rx, a specialty pharmaceutical company leveraging its PharmFilm® technology to develop and bring to market products that improve patient outcomes and address unmet needs, today announced the appointment of James S. Scibetta to the company’s board of directors.
Mr. Scibetta brings a wealth of specialty
pharmaceutical industry experience to the MonoSol Rx board of
directors. In his current role as President of Pacira
Pharmaceuticals (Nasdaq: PCRX), he oversees the day-to-day operations
of the Customer and Patient Solutions group, and its commercial
activities related to the flagship product EXPAREL®, and also directs
the company’s Science Center Campus and UK entity activities related to
manufacturing, technology transfer, and R&D. From 2008
through May 2016, Mr. Scibetta was CFO, and he led the company’s IPO in
2011. As part of the executive team at Pacira, Mr. Scibetta
helped the company transition from a business model centered around
royalty-based licensing of a drug delivery technology, into a fully
integrated developer of proprietary commercialized products. Mr.
Scibetta also serves on the Board of Matinas BioPharma (NYSE: MTNB), a
clinical stage specialty pharma company using its proprietary,
lipid-crystal, nanoparticle delivery technology to provide oral
administration of anti-infective medicines which today are only able to
be delivered intravenously.
Before joining Pacira, Mr. Scibetta was
CFO of Bioenvision Inc. (Nasdaq: BIVN) where he was instrumental in
completing the $345 million sale of the company to Genzyme Corporation,
and he was CFO of Merrimack Pharmaceuticals Inc. Additionally,
Mr. Scibetta has spent more than a decade in investment banking, where
he sourced and executed transactions for a broad base of public and
private healthcare and life sciences companies. Mr. Scibetta
received his Bachelor of Science in Physics from Wake Forest University
and a Master of Business Administration from the University of Michigan.
“Jim offers several decades of knowledge and experience to our company’s board, and his contributions will be important to the company’s continued growth,” said Keith Kendall, CEO of MonoSol Rx. “We look forward to Jim’s added perspective as MonoSol Rx transitions to developing and commercializing its own set of proprietary products. Jim’s experience is a great fit for where we see the future of the company.”
“I am pleased to join the board of
directors at MonoSol Rx and look forward to working closely with the
board and management team to extend the company’s reach into new market
segments,” said James Scibetta, President of Pacira. “The company’s
growing portfolio of commercial and development stage products have the
potential to offer a better delivery option, underpinned by MonoSol
Rx’s best-in class technology, for patients suffering from a variety of
About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm technology to develop products that improve patient outcomes and address unmet needs. PharmFilm can benefit patients by improving the efficacy, safety, and compliance of pharmaceutical products. MonoSol Rx's leadership in film drug technology is supported by strong IP protection, a robust pipeline of prescription drug formulations, and two FDA-approved products — Suboxone® (buprenorphine and naloxone) sublingual film and Zuplenz® (ondansetron) oral soluble film. For press releases and other company information, visit www.monosolrx.com.